Placebo DISKUS

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 3

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01879410

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-06-13End: 2014-01-09Updated: 2017-11-08

Phase 4

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

CompletedNCT00296491

GlaxoSmithKlineAsthma

Start: 2005-09-30End: 2007-10-31Updated: 2016-12-16

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT02982187

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-12-30End: 2017-06-19Updated: 2019-10-21

Related Papers

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

UNC Libraries2021-06-24

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

2019-06-291 citations

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

Respiratory Medicine2015-05-0881 citations